POEM: A PrOspective Registry of Pediatric Cellular Therapy Patients at risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS),
Role: Investigator,
Duke University,
(12/2024 - 12/2025)
Status: Approved
For Profit Organization
SWOG-S0820: A double blind placebo-controlled trial of eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancers in patients with stage 0-III colon cancer, phase III - preventing adenomas of the colon with eflornithine and sulindac (PACES),
Role: Investigator,
Southwest Oncology Group,
(09/2024 - 09/2025)
Status: Approved
SWOG-A081105: randomized study of Erlotinib VS Observation in patients with completely resected Epidermal Growth Factor Receptor (EGFR) mutant Non-small Cell Lung Cancer (NSCLC),
Role: Investigator,
Southwest Oncology Group,
(09/2024 - 09/2025)
Status: Approved
Amgen 20190135: A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (plNN Sotorasib) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation,
Role: Investigator,
Amgen, Inc.,
(02/2025 - 02/2026)
Status: Approved
SWOG S1418/BR006: A randomized phase III trial to evaluate the efficacy and safety of MK-3457 (Pembrolizumab) as adjuvant therapy for triple receptor-negative breast cancer with = 1 cm residual invasive cancer or positive lymph nodes (ypN+) after neoadjuvant chemotherapy,
Role: Investigator,
Southwest Oncology Group,
(12/2024 - 12/2025)
Status: Approved
ATARA Biotherapeutics, Inc. ATA129-EBV-302: Multicenter, Open Label, Phase 3 study of Tabelecleucel for solid organ or allogeneic hematopoietic cell transplant subjects with Epstein-Barr virus-associated post-transplant lymphoproliferative disease after failure of Rituximab or Rituximab and Chemotherapy (ALLELE study),
Role: Investigator,
Atara Biotherapeutics, Inc.,
(12/2024 - 12/2025)
Status: Approved
Southwest Oncology Group (SWOG) S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in rare tumors,
Role: Investigator,
Southwest Oncology Group,
(12/2024 - 12/2025)
Status: Approved
SWOG EA5142:adjuvant nivolumab in resected lung cancers (ANVIL) a randomized phase III study of nivolumab after surgical resection and adjuvant chemotherapy in non-small cell lung cancers,
Role: Investigator,
Southwest Oncology Group,
(11/2024 - 11/2025)
Status: Approved
SWOG-S1216: a phase III randomized trial comparing androgen deprivation therapy + TAK-700 with androgen deprivation therapy + bicalutamide in patients with newly diagnosed metastatic hormone sensitive prostate cancer,
Role: Investigator,
Southwest Oncology Group,
(10/2024 - 10/2025)
Status: Approved
Apollomics Inc. APL-101-01 (SPARTA): Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors,
Role: Investigator,
Apollomics Inc.,
(09/2024 - 09/2025)
Status: Approved
EAP-Oncoceutics-ONC018: Expanded access to ONC201 for patients with H3 K27M-mutant and/or midline high grade gliomas,
Role: Investigator,
Oncoceutics, Inc.,
(10/2022 - 10/2023)
Status: Completed
Astellas 8951-CL-0301: A phase 3, global, multi-center, double-blind, randomized, efficacy study of Zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 as first-line treatment of subjects with Claudin (CLDN) 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma,
Role: Investigator,
Astellas Pharma US, Inc.,
(06/2022 - 06/2023)
Status: Completed
C3441021: A Phase 3, Randomized, Double-Blind, Placebo-Controlled study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (TALAPRO-2),
Role: Investigator,
Pfizer Inc., U.S. Pharmaceuticals Group,
(07/2021 - 07/2022)
Status: Completed
Novartis CACZ885V2301: A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of canakinumab in combination with docetaxel versus placebo in combination with docetaxel in subjects with non-small cell lung cancer (NSCLC) previously treated with PD(L)1 inhibitors and platinum-based chemotherapy (CANOPY-2),
Role: Investigator,
Novartis Pharmaceuticals Corporation,
(09/2020 - 09/2021)
Status: Completed
Retrospective Analysis of Cerebrospinal Fluid in Patients with Hematologic Malignancies Performed at Loma Linda Medical Center from 01/01/2010-12/31/2023 in Adult and Pediatric Patients,
Role: PI,
LLU Dept. of Medicine,
(02/2024)
Status: Approved
Predictors for antibody formation and clinical outcomes in COVID-19 infections in Oncology patients,
Role: PI,
LLU Dept. of Medicine,
(03/2022)
Status: Approved
Zinc and Copper Deficiency's Association with Chronic Anemia,
Role: PI,
LLU Dept. of Medicine,
(03/2022)
Status: Approved
Outcomes including complete vs partial response rate and toxicity profile of Blinatumomab in patient with B-cell acute lymphocytic (B-ALL) at a tertiary medical center,
Role: PI,
LLU Dept. of Medicine,
(01/2022)
Status: Approved
Investigator Initiated: A Retrospective chart review of patients treated with immune checkpoint inhibitors (ICI) to evaluate severe and fatal adverse events in the emergency department,
Role: Investigator,
LLU Dept. of Pharmacy Practice,
(07/2021 - 10/2024)
Status: Completed
Investigator Initiated DLBCL: Retrospective analysis of CNS relapse in patients with diffuse large B cell lymphoma with high CNS IPI scores with or without prophylactic treatment-A single institution study,
Role: PI,
LLU Dept. of Medicine,
(06/2021)
Status: Approved
Convalescent Plasma to Treat Coronavirus - Associated Severe Pulmonary Complications: A Correlation Study of Serologic Anti-SARS-CoV-2 antibody to Treatment Efficacy and Outcome,
Role: Investigator,
LLU Basic Science,
(06/2020)
Status: Approved
Defibrotide prophylaxis in pediatric and adult hematopoietic stem cell transplant recipients: A Retrospective Chart Review (NYMC-217),
Role: Investigator,
LLU Dept. of Medicine,
(07/2024)
Status: Approved
LLU Cancer Center biospecimen laboratory - specimens collection protocol,
Role: Investigator,
LLU Cancer Institute,
(09/2024 - 09/2025)
Status: Approved
Retrospective Analysis of Manganese Deficiency and Anemia at Loma Linda Medical Center from 1/1/2020 – 12/31/2024,
Role: PI,
LLU Cancer Institute,
(03/2025)
Status: Approved
Retrospective Analysis of EASIX Score for Prognostication of Newly Diagnosed Hematologic Malignancies at Loma Linda Medical Center from 1/1/2010 – 12/31/2024,
Role: PI,
LLU Cancer Institute,
(03/2025)
Status: Approved
Non-Profit Organization
The National Marrow donor Program (NMDP) and Center for International Blood and Marrow Transplant Research (CIBMTR) - Contribution of a Blood Sample to the National Marrow Donor Program's Research Sample Repository,
Role: Investigator,
National Marrow Donor Program,
(09/2024 - 09/2025)
Status: Approved
PTCTC ONC1701 (End RAD): A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based on conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative,
Role: Investigator,
Pediatric Blood and Marrow Transplant Consortium,
(06/2024 - 06/2025)
Status: Approved
NMDP and CIBMTR - Protocol for Research Database for Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries.,
Role: Investigator,
National Marrow Donor Program,
(06/2024 - 06/2025)
Status: Approved
National Marrow Donor Program® (NMDP) - 10-CBA: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications,
Role: Investigator,
National Marrow Donor Program,
(09/2024 - 09/2025)
Status: Approved